US Biosecure Act sparks China+1 opportunity for Indian contract development and manufacturing organizations (CDMOs), with Piramal Pharma anticipating significant long-term benefits.

US Biosecure Act sparks China+1 opportunity for Indian contract development and manufacturing organizations (CDMOs), with Piramal Pharma anticipating significant long-term benefits.

The proposed US Biosecure Act, which aims to restrict certain biotech and pharmaceutical contracts involving China, could open up a significant opportunity for Indian contract development and manufacturing organizations (CDMOs) over the next few years. According to...